Undisclosed IPF/ILD Programs
Idiopathic Pulmonary Fibrosis / Interstitial Lung Diseases
Clinical-stage (Phase not specified)Active
Key Facts
Indication
Idiopathic Pulmonary Fibrosis / Interstitial Lung Diseases
Phase
Clinical-stage (Phase not specified)
Status
Active
Company
About Transpire Bio
Transpire Bio is a private, clinical-stage biotech company applying its patented inhalation technology to unlock value from established drug molecules. The company operates a three-pronged business model targeting innovative biopharmaceuticals, co-development partnerships, and complex generics, with an initial pipeline focus on idiopathic pulmonary fibrosis (IPF). Backed by significant manufacturing infrastructure investment, Transpire aims to create improved therapies in high-potential markets like lung disease, CNS, oncology, and obesity.
View full company profile